April 2016 - Cancer Currents Blog
- The Cancer Community's Next Steps for the Moonshot Initiative
The National Cancer Moonshot Initiative’s Blue Ribbon Panel is moving quickly to develop recommendations on how to accelerate progress against cancer.
- Targeted Photoimmunotherapy Approach for Cancer Moves Forward
Two new studies from NCI researchers add to growing evidence of the promise of a novel type of cancer immunotherapy that uses infrared light to activate rapid and selective killing of cancer cells.
- New Treatment Target Identified for Key Prostate Cancer Driver
Researchers have identified a potential alternative approach to blocking a key molecular driver of an advanced form of prostate cancer, called androgen-independent or castration-resistant prostate cancer.
- A Shared Commitment for Accelerating Progress with the Cancer Moonshot
At the AACR annual meeting, Vice President Biden spoke about the National Cancer Moonshot Initiative and the critical role the entire research community will play in accelerating progress against cancer.
- Pembrolizumab Shows Promise in Patients with Rare Form of Skin Cancer
In a small clinical trial, more than half of the patients with an aggressive form of skin cancer called Merkel cell carcinoma responded to the immunotherapy drug pembrolizumab.
- Vitamin D Deficiency May Promote Spread of Some Breast Cancers
Low vitamin D levels are associated with metastasis in women with breast cancer, suggests a new study.
- Toward Precision Therapy for Children with Cancer: An Interview with Dr. Javed Khan
NCI’s Dr. Javed Khan discusses a new NCI clinical program and the promise and challenges of genome-guided therapy for children with cancer.
- Nanoparticle Generator Slips Chemotherapy Past Tumor Cells’ Protective Barriers
Researchers have developed a new injectable nanoparticle-generating technology that can deliver a cancer drug to the nucleus of metastatic breast cancer cells.
- Sunitinib and Sorafenib Ineffective as Adjuvant Therapies for Kidney Cancer
Results from a recent clinical trial show that post-surgical therapy with two anti-angiogenesis drugs does not improve progression-free survival for patients with kidney cancer and may cause serious side effects.
- Drug Combination Shrinks Duodenal Polyps in People with Familial Adenomatous Polyposis
In a small clinical trial of people with an inherited condition that greatly increases gastrointestinal cancer risk, a two-drug combination shrank precancerous lesions in the duodenum.